UNSPSC 51287004: Dapsone

This classification denotes a sulfone anti-infective agent with the molecular formula C12H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W5C518302, chemically known as 4,4-sulphonyldianiline but more generally known as dapsone, which bears US NIH Compound Identifier 2955. European Medicines Agency schedules Dapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06909MIG. The term DAPSONE is an International Non-Proprietary Name.

The World Health Organization schedules dapsone in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N.

UNSPSC 51287004 Dapsone (Commodity) does not reflect active state and local procurement activity relevant to its nominal scope. The two recent opportunities tagged to this code involve Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone — none of which are dapsone — suggesting a cataloging mismatch rather than actual demand for the antimicrobial pharmaceutical named by the code.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026, for antibiotic tablets supplied under an Invitation for Bid process with a total value of $2,999,999.11 across a 12-month initial term plus two renewal options. Separately, Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though the posted response date of July 26, 2023 appears inconsistent with the 2026 posting date. Neither opportunity documents procurement of dapsone itself, and the code's utility for targeting state and local buyers of this specific pharmaceutical is unclear given the recent activity does not align with its stated commodity.